Grubb N G, Rudy D W, Brater D C, Hall S D
Division of Clinical Pharmacology, Department of Medicine, Indiana University School of Medicine, Roudebush Veterans Affairs Medical Center and, Wishard Memorial Hospital, Indianapolis, IN, USA.
Br J Clin Pharmacol. 1999 Oct;48(4):494-500. doi: 10.1046/j.1365-2125.1999.00046.x.
To assess if futile cycling of ketoprofen occurs in patients with decreased renal function.
Ketoprofen was administered to six haemodialysis-dependent patients with end-stage renal disease as single (50 mg) or multiple doses (50 mg three times daily, for 7 days). Plasma and dialysate concentrations of the unconjugated and glucuronidated R- and S-enantiomers of ketoprofen were determined using h.p.l.c. following the single and multiple dosing.
The oral clearance was decreased and terminal elimination half-lives of R- and S-ketoprofen and the corresponding acyl glucuronides were increased in functionally anephric patients compared with healthy subjects. In contrast with the R-isomers, S-ketoprofen and S-ketoprofen glucuronide exhibited an unexpected accumulation (2.7-3. 8 fold) after repeated dosing achieving S:R ratios of 3.3+/-1.7 and 11.2+/-5.3, respectively. The plasma dialysis clearances for R- and S-ketoprofen glucuronides were 49.4+/-19.8 and 39.0+/-15.9 ml min-1, respectively, and 10.8+/-17.6 and 13.3+/-23.5 ml min-1 for unconjugated R- and S-ketoprofen.
The selective accumulation of S-ketoprofen and its acyl glucuronide are consistent with amplification of chiral inversion subsequent to futile cycling between R-ketoprofen and R-ketoprofen glucuronide. Severe renal insufficiency, and possibly more modest decrements, results in a disproportionate increase in systemic exposure to the S-enantiomer which inhibits both pathologic and homeostatic prostaglandin synthesis.
评估肾功能减退患者是否会出现酮洛芬的无效循环。
对6例终末期肾病依赖血液透析的患者给予酮洛芬,单次剂量(50mg)或多次剂量(50mg,每日3次,共7天)。单次和多次给药后,采用高效液相色谱法测定血浆和透析液中酮洛芬未结合型和葡萄糖醛酸结合型的R-和S-对映体浓度。
与健康受试者相比,功能性无肾患者的口服清除率降低,R-和S-酮洛芬及其相应的酰基葡萄糖醛酸的终末消除半衰期延长。与R-异构体不同,S-酮洛芬和S-酮洛芬葡萄糖醛酸在重复给药后出现意外蓄积(2.7 - 3.8倍),S:R比值分别达到3.3±1.7和11.2±5.3。R-和S-酮洛芬葡萄糖醛酸的血浆透析清除率分别为49.4±19.8和39.0±15.9 ml·min⁻¹,未结合型R-和S-酮洛芬的血浆透析清除率分别为10.8±17.6和13.3±23.5 ml·min⁻¹。
S-酮洛芬及其酰基葡萄糖醛酸的选择性蓄积与R-酮洛芬和R-酮洛芬葡萄糖醛酸之间无效循环后手性转化的放大一致。严重肾功能不全,可能还有更轻微的肾功能减退,会导致S-对映体的全身暴露不成比例增加,从而抑制病理性和稳态性前列腺素的合成。